APT’s first co-sponsored PhD project has now started at Aston University. The PhD will provide insight into how iDPC can formulate amino acids as adjuvants

APT’s first undergraduate placement has come to an end. Tahreem Javaid was a great asset to the company over the past year and has put

APT are delighted to welcome two new sandwich degree placement students to our team. Isobel Clark is joining from Aston University’s Biomedical Science course and

APT are excited to announce that the fundamental Patent covering the iDPC technology has been granted in the US and Japan in summer 2021 following

Congratulations to Professor Afzal Mohammed for the award of an MIBTP and BBSRC funded PhD looking at the Mechanistic evaluation of amino acids as adjuvants

The APT team has expanded! We are excited to announce that Amandip Gill has joined APT as a Formulation/Research Scientist and we have taken on

After a short shutdown due to the current Coronavirus pandemic APT are excited to be resuming R&D and lab work! Aston University is now on

Aston Particle Technologies is delighted to announce publishing of its first Trademark – APT-Hale™. APT-Hale™ is APT’s unique platform for manufacture of dry powder inhalers

*Update January 2020 APT’s first patent covering the iDPC technology has been granted in Europe. Review process is still underway in the USA, Japan and